

-> b reg  
 FILE 'REGISTRY' ENTERED AT 17:34:29 ON 02 OCT 2008  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
 provided by InfoChem.

STRUCTURE FILE UPDATES: 1 OCT 2008 HIGHEST RN 1056151-32-6  
 DICTIONARY FILE UPDATES: 1 OCT 2008 HIGHEST RN 1056151-32-6

New CAS Information Use Policies, enter HELP USAGETERMS for details.


TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when  
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
 predicted properties as well as tags indicating availability of  
 experimental property data in the original document. For information  
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndec/properties.html>

=> d que sta 112  
 L8 STR



REP G1-(O-19) A  
 VAR G2=C/N  
 NODE ATTRIBUTES:  
 DEFAULT MLEVEL IS ATOM  
 DEFAULT ELEVEL IS LIMITED  
 ECOUNT IS E3 C E2 N AT 1  
 ECOUNT IS E8 C E1 O AT 11

GRAPH ATTRIBUTES:  
 RING(S) ARE ISOLATED OR EMBEDDED  
 NUMBER OF NODES IS 11

STEREO ATTRIBUTES: NONE  
 L10 11255 SEA FILE-REGISTRY ABB=ON PLU=ON (NCNC2 OR N2C3)/ES AND  
 CCA-C6/ES  
 L12 76 SEA FILE-REGISTRY SUB=L10 SSS FUL L8

100.0% PROCESSED 2253 ITERATIONS 76 ANSWERS  
 SEARCH TIME: 00.00.01

=> b hcap  
 FILE 'HCAPIUS' ENTERED AT 17:34:34 ON 02 OCT 2008  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is  
 held by the publishers listed in the PUBLISHER (PB) field (available  
 for records published or updated in Chemical Abstracts after December  
 26, 1996), unless otherwise indicated in the original publications.  
 The CA Lexicon is the copyrighted intellectual property of the  
 the American Chemical Society and is provided to assist you in searching  
 databases on STN. Any dissemination, distribution, copying, or storing  
 of this information, without the prior written consent of CAS, is

strictly prohibited.

FILE COVERS 1907 - 2 Oct 2008 VOL 149 ISS 14  
FILE LAST UPDATED: 1 Oct 2008 (20081001/ED)

HCplus now includes complete International Patent Classification (IPC)  
reclassification data for the second quarter of 2008.

New CAS Information Use Policies, enter HELP USAGETERMS for details.

This file contains CAS Registry Numbers for easy and accurate  
substance identification.

=> d bib abs hitrn fhitr 117 tot



-> d bib abs hitrn hitstr 118 tot

118 ABSTRACT OF 5 MCASPUS COPYRIGHT 2018 ACS on 5/18  
 119 2018-1019628 MCASPUS  
 120 149158336  
 121  
 122 Therapeutic agent for diabetic material  
 123 IRIKI, KUNIO; SAITO, MAKI  
 124 School Jurisprud Person Kitasato Institute, Japan  
 125 DCT Int. Appl., & App.  
 126 COIN: PXXXX  
 127  
 128 Date:  
 129 Japanese

PI	DATA	SUBJECT NO.	INFO	DATE	APPLICATION NO.	DATE
PI	MS-00149		A3	10081811	10180-000501239	10081812
	16C	AL	AP	AL	AL	AP
	CA	CA	CA	CA	CA	CA
	CH	CH	CH	CH	CH	CH
	CI	CI	CI	CI	CI	CI
	CO	CO	CO	CO	CO	CO
	CR	CR	CR	CR	CR	CR
	CS	CS	CS	CS	CS	CS
	CT	CT	CT	CT	CT	CT
	CU	CU	CU	CU	CU	CU
	CV	CV	CV	CV	CV	CV
	CW	CW	CW	CW	CW	CW
	CX	CX	CX	CX	CX	CX
	CY	CY	CY	CY	CY	CY
	CZ	CZ	CZ	CZ	CZ	CZ
	DA	DA	DA	DA	DA	DA
	DB	DB	DB	DB	DB	DB
	DC	DC	DC	DC	DC	DC
	DD	DD	DD	DD	DD	DD
	DE	DE	DE	DE	DE	DE
	DF	DF	DF	DF	DF	DF
	DG	DG	DG	DG	DG	DG
	DH	DH	DH	DH	DH	DH
	DI	DI	DI	DI	DI	DI
	DJ	DJ	DJ	DJ	DJ	DJ
	DK	DK	DK	DK	DK	DK
	DL	DL	DL	DL	DL	DL
	DM	DM	DM	DM	DM	DM
	DN	DN	DN	DN	DN	DN
	DO	DO	DO	DO	DO	DO
	DP	DP	DP	DP	DP	DP
	DQ	DQ	DQ	DQ	DQ	DQ
	DR	DR	DR	DR	DR	DR
	DS	DS	DS	DS	DS	DS
	DT	DT	DT	DT	DT	DT
	DU	DU	DU	DU	DU	DU
	DV	DV	DV	DV	DV	DV
	DW	DW	DW	DW	DW	DW
	DX	DX	DX	DX	DX	DX
	DY	DY	DY	DY	DY	DY
	DZ	DZ	DZ	DZ	DZ	DZ
	EA	EA	EA	EA	EA	EA
	EB	EB	EB	EB	EB	EB
	EC	EC	EC	EC	EC	EC
	ED	ED	ED	ED	ED	ED
	EE	EE	EE	EE	EE	EE
	EF	EF	EF	EF	EF	EF
	EG	EG	EG	EG	EG	EG
	EH	EH	EH	EH	EH	EH
	EI	EI	EI	EI	EI	EI
	EJ	EJ	EJ	EJ	EJ	EJ
	EK	EK	EK	EK	EK	EK
	EL	EL	EL	EL	EL	EL
	EM	EM	EM	EM	EM	EM
	EN	EN	EN	EN	EN	EN
	EO	EO	EO	EO	EO	EO
	EP	EP	EP	EP	EP	EP
	EQ	EQ	EQ	EQ	EQ	EQ
	ER	ER	ER	ER	ER	ER
	ES	ES	ES	ES	ES	ES
	ET	ET	ET	ET	ET	ET
	EU	EU	EU	EU	EU	EU
	EV	EV	EV	EV	EV	EV
	EW	EW	EW	EW	EW	EW
	EX	EX	EX	EX	EX	EX
	EY	EY	EY	EY	EY	EY
	EZ	EZ	EZ	EZ	EZ	EZ
	FA	FA	FA	FA	FA	FA
	FB	FB	FB	FB	FB	FB
	FC	FC	FC	FC	FC	FC
	FD	FD	FD	FD	FD	FD
	FE	FE	FE	FE	FE	FE
	FF	FF	FF	FF	FF	FF
	FG	FG	FG	FG	FG	FG
	FH	FH	FH	FH	FH	FH
	FI	FI	FI	FI	FI	FI
	FJ	FJ	FJ	FJ	FJ	FJ
	FK	FK	FK	FK	FK	FK
	FL	FL	FL	FL	FL	FL
	FM	FM	FM	FM	FM	FM
	FN	FN	FN	FN	FN	FN
	FO	FO	FO	FO	FO	FO
	FP	FP	FP	FP	FP	FP
	FQ	FQ	FQ	FQ	FQ	FQ
	FR	FR	FR	FR	FR	FR
	FS	FS	FS	FS	FS	FS
	FT	FT	FT	FT	FT	

2017-2028195555	A	200209210	2017-2017-8000212923	200792314
PRSA1	2017-2017-8000312923	A	200792314	

The present invention provides a therapeutic compound which has effective delay activity on the progress of diabetic cataract. The therapeutic agent comprises an antioxidant agent capable of preventing the impaired state of the lens protein caused by the action of an oxidant agent as well as being a p-tyrosine compound having a specific structure or a pharmacologically acceptable salt thereof. It is found that an antioxidant agent having a specific structure described herein has an antioxidant activity and also has an efficient anti-diabetic cataract activity. Based on this finding, it becomes possible to provide a novel therapeutic strategy for cataract.

1048370-27-9F	1048370-30-6F	1048370-32-5F
1048370-34-8F	1048370-35-9F	1048370-36-0F
1048370-38-2F	1048370-39-3F	1048370-40-6F
1048370-41-7F	1048370-44-0F	1048370-45-1F
1048370-48-4F	1048370-52-9F	1048370-52-0F
1048370-53-2F	1048370-55-3F	1048370-58-6F

RI = RAC (Pharmacological activity); PKY (Pharmacokinetics); SYN (Synthetic preparation); THZ (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

```


10648370-27-3F 10648370-30-4F 10648370-32-5F
10648370-34-6F 10648370-35-6F 10648370-36-6F
10648370-38-7F 10648370-39-7F 10648370-40-6F
10648370-41-7F 10648370-44-8F 10648370-45-1F
10648370-48-6F 10648370-51-8F 10648370-52-0F
10648370-53-3F 10648370-55-3F 10648370-58-6F

```


1248572-89-7P  
 PL PAC (Pharmacological activity); PKT (Pharmacokinetics); SYN (Synthetic preparation); TNE (Therapeutic use); BIOL (Biological study); PREP (Preparation); Q526 (User)

CS Methacrosin, (2,3-dihydro-5-hydroxy-2,4,6,7-tetramethyl-1-benzofuran-1-yl)-[4-(3-  
(1*H*-imidazol-2-yl)phenyl)-3-piperidinyl]- (CA INDEX NAME)


118 ASHOK, J. DE S. INCRUSTED CORRELATION WITH ACS ON STM (CONTINUED)



CS Methanone, [5-(acetyloxy)-2,3-dihydro-1,4,6,7-tetramethyl-2-benzofuranyl][4-[3-(2H-imidazol-1-yl)phenyl]-1-piperazinyl]- (CA INCKZ NAME)




RN 1049370-24-9 INCAPUS  
 CN INDEX NAME NOT YET ASSIGNED




BSR 1048370-26-0 10CAPC/33


118 ASSHES 1 OF 5 HCAPLUS COPYRIGHT 2018 ACS on STD (Continued)  
 05 5-tetrafluoranyl, 2,3-dihydro-2,4,6,7-tetramethyl-2-[[4-[4-(1H-pyrazol-5-yl)phenyl]-3-piperazinyl)methyl]- (CA INDEX NAME)



008 1249270-28-2 HCAW/LJB  
009 INDEX NAME NOT YET ASSIGNED




DOI: 10.4039/bot2006.100.100




DOI 10.48270-40-6 NCA95/08

Metazone, [1-(2-ethoxy-2,3-dihydro-2,4,4,7-tetramethyl-2H-benzofuran-5-yl)-4-(4-(2H-pyrazol-3-yl)phenyl)-1H-piperazinyl]- (CA INDEX)




PG# 1049270-41-7 HCAFL008

CS 8-benzofuran-2-yl-3-oxidihydro-2,4,4,7-tetramethyl-2H-[1,4]oxa(1H)-pyranol-3-yl]phenyl]-2-piperazinyl)methyl-, 5-monoate (CA INDEX NAME)




REF ID: A649270-44-0 102APR/13


138 ASSESS. 2 OF 5: BCDPUBS: COPYRIGHT 2018 ACS on STM (Continued)  
ON INDEX NAME NOT YET ASSIGNED



CH INDEX NAME NOT YET ASSIGNED



CR 5-Benzofuranol, 2,3-dihydro-  
4-methyl-, 2-methyl-*trans*-2,3-epoxy-



NO 1040270-51-9 HCBPL/08






FIG. 1040330-65-0 HCNFL38




DOI: 10.4923/10-52-3 187875/13

CS Methanesulfonyl-2,3-dihydro-2,4,6,7-tetramethyl-2-benzofuranyl[[6-[3-(1H-pyrazol-1-yl)phenyl]-1-piperazinyl]]- (CA 13800)


1-18 ANSWER 2 OF 5 INCORRECT CORRECT 2000 ACS 60 31




CA 1046270-16-2 HCBP0128  
5-Benzofuranol, 2,3-dihydro-2,4,4,7-tetramethyl-2-[(4-{3-[(1H-pyrazol-3-yl)phenyl]-3-piperonylmethyl}-, 5-acetate (CA INDEX NAME)



DB 1048370-58-6 MCANPLUS  
CN INDEX NAME NOT YET ASSIGNED



RM 1048370-59-7 HCAPLUS  
CN ENTRY NAME NOT YET ASSIGNED



RE CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD  
ALL CITATIONS AVAILABLE IN THE RE FORMAT

118 ANDROS 2 OF 5  
 AN 2007.505611 BOARPLS  
 IN 146.505679  
 TT Generation of amphetamine derivatives and related compounds as anti-cancer drugs  
 IN Takebayashi, Shiro; Ueda, Nobuhito; Uchida, Seisichi  
 SA Nippon Soda Co., Ltd., Japan  
 30 INT Int. Appl. Napp.  
 CDSN: PEXC02  
 DT Patent  
 LA Japanese  
 FAN C02 1

[illegible]

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

[illegible]

118 ANSWER 2 OF 5: INCARCERATION COPYRIGHT 2018 ACS on 5TH (Continued)



ZN 934214-39-6 KICAGLOS  
 CH 5-benzofuranamine, 2,3-dihydro-4-[[4-[[4-(1H-indazol-1-yl)phenyl]methyl]-1-piperazinyl]methyl]-2,2,6,7-tetraazabicyclo- (CA INDEX NAME)

CC(C)C

CS 5-Methyluracil, 2,3-dihydro-2,6,7-trimethyl-4-[4-(4-cin-oxazol-2


118 ANSWER 2 OF 5: BCADWAS COPYRIGHT 2010 ACS on STM (Continued)  
yl)phenyl)methyl]-1-piperazinyl)methyl]- (CA INDEX NAME)



UN 336214-3E-9 HCAPLUG  
 CN 5-Methyl-2-(2,3-dihydro-2,2,6,7-tetraoxo-1H-4-[1H-1,2,4-triazol-1-yl]-1H-1,2,4-triazol-5-yl)-1H-1,2,4-triazol-4-ol


## 114 ASSESS 1 OF 5 NONPULSE COPYRIGHT 2004 ACS on STM (Continued)

[1-(phenyl)-3-pyridinyl)methyl]- (CA INDEX NAME)



115 13N111-11-0 NONPULSE

N-Benzofuranone, 4-[(1,3-dihydro-4-[(10-oxo-1,2,3-dihydro-2,2,4,4-tetrahydro-1H-benzothiazepin-1-yl)methyl]-1H-benzothiazepin-10-yl)methyl]-1,3-dihydro-2,2,4,4-tetrahydro-1H-benzothiazepin-10-yl- (CA INDEX NAME)



116 13N111-11-1 UP

A1 [C] (abstract) [UP] (synthetic preparation) [UP] (preparation) [NCT] (therapeutic use) [NCT] (therapeutic use)

N-Benzofuranone, 4-[(1,3-dihydro-4-[(10-oxo-1,2,3-dihydro-2,2,4,4-tetrahydro-1H-benzothiazepin-1-yl)methyl]-1H-benzothiazepin-10-yl)methyl]-1,3-dihydro-2,2,4,4-tetrahydro-1H-benzothiazepin-10-yl- (CA INDEX NAME)



## 114 ASSESS 3 OF 5 NONPULSE COPYRIGHT 2004 ACS on STM

117 13N111-11-1 UP

118 13N111-11-1 UP

Preparation of nitrogen-containing heterocycles as antineoplastic and their pharmaceutical uses

119 13N111-11-1 UP

120 13N111-11-1 UP

121 13N111-11-1 UP

122 13N111-11-1 UP

123 13N111-11-1 UP

124 13N111-11-1 UP

125 13N111-11-1 UP

126 13N111-11-1 UP

127 13N111-11-1 UP

128 13N111-11-1 UP

129 13N111-11-1 UP

130 13N111-11-1 UP

131 13N111-11-1 UP

132 13N111-11-1 UP

133 13N111-11-1 UP

134 13N111-11-1 UP

135 13N111-11-1 UP

136 13N111-11-1 UP

137 13N111-11-1 UP

138 13N111-11-1 UP

139 13N111-11-1 UP

140 13N111-11-1 UP

141 13N111-11-1 UP

142 13N111-11-1 UP

143 13N111-11-1 UP

144 13N111-11-1 UP

145 13N111-11-1 UP

146 13N111-11-1 UP

147 13N111-11-1 UP

148 13N111-11-1 UP

149 13N111-11-1 UP

150 13N111-11-1 UP

151 13N111-11-1 UP

152 13N111-11-1 UP

153 13N111-11-1 UP

154 13N111-11-1 UP

155 13N111-11-1 UP

156 13N111-11-1 UP

157 13N111-11-1 UP

158 13N111-11-1 UP

159 13N111-11-1 UP

160 13N111-11-1 UP

161 13N111-11-1 UP

162 13N111-11-1 UP

163 13N111-11-1 UP

164 13N111-11-1 UP

165 13N111-11-1 UP

166 13N111-11-1 UP

167 13N111-11-1 UP

168 13N111-11-1 UP

169 13N111-11-1 UP

170 13N111-11-1 UP

171 13N111-11-1 UP

172 13N111-11-1 UP

173 13N111-11-1 UP

174 13N111-11-1 UP

175 13N111-11-1 UP

176 13N111-11-1 UP

177 13N111-11-1 UP

178 13N111-11-1 UP

179 13N111-11-1 UP

180 13N111-11-1 UP

181 13N111-11-1 UP

182 13N111-11-1 UP

183 13N111-11-1 UP

## 114 ASSESS 1 OF 5 NONPULSE COPYRIGHT 2004 ACS on STM (Continued)

[1-(phenyl)-3-pyridinyl)methyl]- (CA INDEX NAME)



115 13N111-11-0 NONPULSE

N-Benzofuranone, 4-[(1,3-dihydro-4-[(10-oxo-1,2,3-dihydro-2,2,4,4-tetrahydro-1H-benzothiazepin-1-yl)methyl]-1H-benzothiazepin-10-yl)methyl]-1,3-dihydro-2,2,4,4-tetrahydro-1H-benzothiazepin-10-yl- (CA INDEX NAME)



116 13N111-11-1 UP

A1 [C] (abstract) [UP] (synthetic preparation) [UP] (preparation) [NCT] (therapeutic use) [NCT] (therapeutic use)

N-Benzofuranone, 4-[(1,3-dihydro-4-[(10-oxo-1,2,3-dihydro-2,2,4,4-tetrahydro-1H-benzothiazepin-1-yl)methyl]-1H-benzothiazepin-10-yl)methyl]-1,3-dihydro-2,2,4,4-tetrahydro-1H-benzothiazepin-10-yl- (CA INDEX NAME)



## 114 ASSESS 4 OF 5 NONPULSE COPYRIGHT 2004 ACS on STM

117 13N111-11-1 UP

118 13N111-11-1 UP

Preparation of nitrogen-containing heterocycles as antineoplastic and their pharmaceutical uses

119 13N111-11-1 UP

120 13N111-11-1 UP

121 13N111-11-1 UP

122 13N111-11-1 UP

123 13N111-11-1 UP

124 13N111-11-1 UP

125 13N111-11-1 UP

126 13N111-11-1 UP

127 13N111-11-1 UP

128 13N111-11-1 UP

129 13N111-11-1 UP

130 13N111-11-1 UP

131 13N111-11-1 UP

132 13N111-11-1 UP

133 13N111-11-1 UP

134 13N111-11-1 UP

135 13N111-11-1 UP

136 13N111-11-1 UP

137 13N111-11-1 UP

138 13N111-11-1 UP

139 13N111-11-1 UP

140 13N111-11-1 UP

141 13N111-11-1 UP

142 13N111-11-1 UP

143 13N111-11-1 UP

144 13N111-11-1 UP

145 13N111-11-1 UP

146 13N111-11-1 UP

147 13N111-11-1 UP

148 13N111-11-1 UP

149 13N111-11-1 UP

150 13N111-11-1 UP

151 13N111-11-1 UP

152 13N111-11-1 UP

153 13N111-11-1 UP

154 13N111-11-1 UP

155 13N111-11-1 UP

156 13N111-11-1 UP

157 13N111-11-1 UP

158 13N111-11-1 UP

159 13N111-11-1 UP

160 13N111-11-1 UP

161 13N111-11-1 UP

162 13N111-11-1 UP

163 13N111-11-1 UP

164 13N111-11-1 UP

165 13N111-11-1 UP

166 13N111-11-1 UP

167 13N111-11-1 UP

168 13N111-11-1 UP

169 13N111-11-1 UP

170 13N111-11-1 UP

171 13N111-11-1 UP

172 13N111-11-1 UP

173 13N111-11-1 UP

174 13N111-11-1 UP

175 13N111-11-1 UP

176 13N111-11-1 UP

177 13N111-11-1 UP

178 13N111-11-1 UP

179 13N111-11-1 UP

180 13N111-11-1 UP

181 13N111-11-1 UP

182 13N111-11-1 UP

183 13N111-11-1 UP

184 13N111-11-1 UP

185 13N111-11-1 UP

186 13N111-11-1 UP

187 13N111-11-1 UP

188 13N111-11-1 UP

189 13N111-11-1 UP

190 13N111-11-1 UP

191 13N111-11-1 UP

192 13N111-11-1 UP

193 13N111-11-1 UP

194 13N111-11-1 UP

195 13N111-11-1 UP

196 13N111-11-1 UP

197 13N111-11-1 UP

198 13N111-11-1 UP

199 13N111-11-1 UP

200 13N111-11-1 UP

201 13N111-11-1 UP

202 13N111-11-1 UP

203 13N111-11-1 UP

204 13N111-11-1 UP

205 13N111-11-1 UP

206 13N111-11-1 UP

207 13N111-11-1 UP

208 13N111-11-1 UP

209 13N111-11-1 UP

210 13N111-11-1 UP

211 13N111-11-1 UP

212 13N111-11-1 UP

213 13N111-11-1 UP

214 13N111-11-1 UP

215 13N111-11-1 UP

216 13N111-11-1 UP

217 13N111-11-1 UP

218 13N111-11-1 UP

219 13N111-11-1 UP

220 13N111-11-1 UP

221 13N111-11-1 UP

222 13N111-11-1 UP

223 13N111-11-1 UP

224 13N111-11-1 UP

225 13N111-11-1 UP

226 13N111-11-1 UP

227 13N111-11-1 UP

228 13N111-11-1 UP

229 13N111-11-1 UP

230 13N111-11-1 UP

231 13N111-11-1 UP

232 13N111-11-1 UP

233 13N111-11-1 UP

234 13N111-11-1 UP

235 13N111-11-1 UP

236 13N111-11-1 UP

237 13N111-11-1 UP

238 13N111-11-1 UP

239 13N111-11-1 UP

240 13N111-11-1 UP

241 13N111-11-1 UP

242 13N111-11-1 UP

243 13N111-11-1 UP

244 13N111-11-1 UP

245 13N111-11-1 UP

246 13N111-11-1 UP

247 13N111-11-1 UP

248 13N111-11-1 UP

249 13N111-11-1 UP

250 13N111-11-1 UP

251 13N111-11-1 UP

252 13N111-11-1 UP

253 13N111-11-1 UP

254 13N111-11-1 UP

255 13N111-11-1 UP

256 13N111-11-1 UP

257 13N111-11-1 UP

258 13N111-11-1 UP

259 13N111-11-1 UP

260 13N111-11-1 UP

261 13N111-11-1 UP

262 13N111-11-1 UP

263 13N111-11-1 UP

264 13N111-11-1 UP

265 13N111-11-1 UP

266 13N111-11-1 UP

267 13N111-11-1 UP

268 13N111-11-1 UP

269 13N111-11-1 UP

270 13N111-11-1 UP

271 13N111-11-1 UP

272 13N111-11-1 UP

273 13N1

08 HARDAT 131:322629



```
-> b uspatall
FILE 'USPATFULL' ENTERED AT 17:35:08 ON 02 OCT 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATOLD' ENTERED AT 17:35:08 ON 02 OCT 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 17:35:08 ON 02 OCT 2008
CA INDEXING COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

-> d bib abs hitrn fhitstr 120 tot
```

[illegible][illegible][illegible]

128 ANSWER 2 OF 2 USEFUL on STX (Continued)

```

L20 ANNOTS 2 OF 2 USPATFILE OR STE
AI 2006/269234 USPATFILE
TI Benzoylurea compounds production process and intermediates
DE Doshi, Hoshino, Katsunaga-koh, JAPAN
MOCHIZUKI, HOSONO, KATSUNAGA-KOH, JAPAN
Takahide, Seisichi, Katsunaga-koh, JAPAN
Ehikawa, Mitsumasa, Katsunaga-koh, JAPAN
Tsubokawa, Shiro, Katsunaga-koh, JAPAN
Shimada, Yumiko, Katsunaga-koh, JAPAN
Shirato, Fumio, Katsunaga-koh, JAPAN
MORIO, HISAKO, Katsunaga-koh, JAPAN
PR 2006/020000, Mod. 2 JPO/US (non-US corporations)
DE 2006/020000
DE 2006/020000 AI 2006/030 (SI)
AI 2006/020000 AI 2006/030
AI 2006/020000 AI 2006/030

```

PRJ	2003JP-008295621	20038901
	2003JP-008291881	20038911
	2003JP-008298443	20038922
	2004JP-008022858	20048130
	2004JP-008023583	20048130

ST	Utility
FS	APPLICATION
INVENTOR	DARBY & DARBY P. C., P. O. BOX 5257, NEW YORK, NY, 10158-5257, US
CLASS	Number of Claims: 22
REL	Exemplary Claim: 1

CAS INDEXING IS AVAILABLE FOR THIS PARTIAL.

The present review lists 100 chemical compounds represented by the following formulae: (1)  $R-O-R$  (2)  $R-O-R$  (3)  $R-O-R$  (4)  $R-O-R$  (5)  $R-O-R$  (6)  $R-O-R$  (7)  $R-O-R$  (8)  $R-O-R$  (9)  $R-O-R$  (10)  $R-O-R$  (11)  $R-O-R$  (12)  $R-O-R$  (13)  $R-O-R$  (14)  $R-O-R$  (15)  $R-O-R$  (16)  $R-O-R$  (17)  $R-O-R$  (18)  $R-O-R$  (19)  $R-O-R$  (20)  $R-O-R$  (21)  $R-O-R$  (22)  $R-O-R$  (23)  $R-O-R$  (24)  $R-O-R$  (25)  $R-O-R$  (26)  $R-O-R$  (27)  $R-O-R$  (28)  $R-O-R$  (29)  $R-O-R$  (30)  $R-O-R$  (31)  $R-O-R$  (32)  $R-O-R$  (33)  $R-O-R$  (34)  $R-O-R$  (35)  $R-O-R$  (36)  $R-O-R$  (37)  $R-O-R$  (38)  $R-O-R$  (39)  $R-O-R$  (40)  $R-O-R$  (41)  $R-O-R$  (42)  $R-O-R$  (43)  $R-O-R$  (44)  $R-O-R$  (45)  $R-O-R$  (46)  $R-O-R$  (47)  $R-O-R$  (48)  $R-O-R$  (49)  $R-O-R$  (50)  $R-O-R$  (51)  $R-O-R$  (52)  $R-O-R$  (53)  $R-O-R$  (54)  $R-O-R$  (55)  $R-O-R$  (56)  $R-O-R$  (57)  $R-O-R$  (58)  $R-O-R$  (59)  $R-O-R$  (60)  $R-O-R$  (61)  $R-O-R$  (62)  $R-O-R$  (63)  $R-O-R$  (64)  $R-O-R$  (65)  $R-O-R$  (66)  $R-O-R$  (67)  $R-O-R$  (68)  $R-O-R$  (69)  $R-O-R$  (70)  $R-O-R$  (71)  $R-O-R$  (72)  $R-O-R$  (73)  $R-O-R$  (74)  $R-O-R$  (75)  $R-O-R$  (76)  $R-O-R$  (77)  $R-O-R$  (78)  $R-O-R$  (79)  $R-O-R$  (80)  $R-O-R$  (81)  $R-O-R$  (82)  $R-O-R$  (83)  $R-O-R$  (84)  $R-O-R$  (85)  $R-O-R$  (86)  $R-O-R$  (87)  $R-O-R$  (88)  $R-O-R$  (89)  $R-O-R$  (90)  $R-O-R$  (91)  $R-O-R$  (92)  $R-O-R$  (93)  $R-O-R$  (94)  $R-O-R$  (95)  $R-O-R$  (96)  $R-O-R$  (97)  $R-O-R$  (98)  $R-O-R$  (99)  $R-O-R$  (100)  $R-O-R$

```

CAS INDEXING IS AVAILABLE FOR THIS MACHINE.
IT
R41294-36-4P R41294-37-7P R41294-38-8P
R41294-39-9P R41294-39-1P R41294-43-6P
R41294-43-7P R41294-44-8P R41294-45-5P
R41294-46-2P R41294-47-3P R41294-50-6P
R41294-51-7P R41294-54-0P R41294-55-1P
R41294-56-2P R41294-57-3P R41294-58-4P
R41294-60-8P R41294-61-9P R41294-63-6P
R41294-74-4P R41294-76-6P R41294-78-2P
R41294-78-4P R41294-79-5P R41294-80-2P
R41294-81-3P R41294-82-4P R41294-84-3P
R41294-84-4P R41294-82-7P R41294-83-5P


```

```

      (preparation of phenylazole derivs. as antiooxidants)
IT 841285-41-3P 841285-42-3P 841285-46-3P
      841285-50-3P
      (preparation of phenylazole derivs. as antiooxidants)
IT 841284-26-4P
      (preparation of phenylazole derivs. as antiooxidants)

```

HN 861294-26-6 USPAIFULL  
 CN 5-Benrofurazamine, 2,3-dihydro-2-[[4-[4-(3H-imidazol-1-yl)phenyl]-1-piperazinyl]ethyl]-2,4,6,7-tetramethyl- (CA INDEX NAME)




-> d bib abs hitstr 121 tot



[illegible]

AB The invention relates to heterocyclic derivatives of formula (II), or pharmaceutically-acceptable salts thereof, which possess antithrombotic and anticoagulant properties and are accordingly useful in methods of treatment of humans or animals. The invention also relates to processes for the preparation of the heterocyclic derivatives, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments for use in the production of an antithrombotic or anticoagulant effect. ##571164

CAS REGISTRY IS AVAILABLE FOR THIS ENTRY.  
 [T] 249292-01-19 249292-19-1P  
 (preparation of 1-betacarylsulfonoyl-4-betacarylsulfonoylpiperazines and  
 analogs as factor Xa inhibitors)  
 KE 249292-01-1 USPATFULL  
 CN Methanone, [4-[(5-chloro-2-benzofuranyl)sulfonoyl]-2-piperazinyl] [(4-[(4H-  
 imidazol-3-ylthio)yl]- (CA INDEX NAME)



CH Methanone, 4-[4-(5-chloro-2-benzofuranyl)sulfonyl]-1-piperazinyl [4-(2-methyl-1*H*-imidazol-5-yl)phenyl]- (CA INDEX NAME)



-> d his

(FILE 'HOME' ENTERED AT 17:15:34 ON 02 OCT 2008)

L1 FILE 'HCAPLUS' ENTERED AT 17:15:48 ON 02 OCT 2008  
1 US20060247228/PN

FILE 'REGISTRY' ENTERED AT 17:15:55 ON 02 OCT 2008

L2 FILE 'HCAPLUS' ENTERED AT 17:16:02 ON 02 OCT 2008  
TRA L1 1- RN : 165 TERMS

L3 FILE 'REGISTRY' ENTERED AT 17:16:03 ON 02 OCT 2008  
165 SEA L2  
L4 123 L3 AND (NCNC2 OR N2C3)/ES  
L5 121 L4 AND C6/ES  
L6 88 L5 AND OC4-C6/ES  
L7 37 L6 AND (NC2NC2 OR NC5)/ES  
L8 STR  
L9 0 L8  
L10 11255 (NCNC2 OR N2C3)/ES AND OC4-C6/ES  
L11 2 L8 SAM SUB-L10  
L12 76 L8 FULL SUB-L10  
SAV TEM J820C1A/A L12  
L13 37 L12 AND L3  
L14 39 L12 NOT L13

FILE 'HCAOLD' ENTERED AT 17:26:49 ON 02 OCT 2008  
L15 0 L13  
L16 0 L14

FILE 'HCAPLUS' ENTERED AT 17:26:59 ON 02 OCT 2008  
L17 2 L13  
L18 5 L14  
SEL HIT RN 4-5

FILE 'REGISTRY' ENTERED AT 17:28:53 ON 02 OCT 2008  
L19 3 E1-3

FILE 'USPATFULL, USPATOLD, USPAT2' ENTERED AT 17:33:47 ON 02 OCT 2008  
L20 2 L13  
L21 3 L14

=>